⁶⁸Ga-DOTATATE positron emission tomography/computed tomography to detect the recurrence of phosphaturic mesenhcymal tumor-induced osteomalacia

Abstract

⁶⁸Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) has shown superiority over¹¹¹Indium-octreotide scanning for the detection of phosphaturic mesenchymal tumors (PMTs). We report a case of tumor-induced osteomalacia resulting from PMT which, although initially clinically suspected, was not localized on octreotide scintigraphy performed several years prior. Subsequent surgical excision of a presumed benign osseous lesion a few years later revealed the diagnosis on pathology. Imaging assessment using ⁶⁸Ga-DOTATATE PET/CT following recent clinical suspicion for recurrence revealed an intense tracer-avid lesion at the primary tumor site. DOTATATE imaging plays an important role in localizing tumors with high somatostatin receptor expression, such as neuroendocrine tumors (pheochromocytoma, paraganglioma, and neuroblastoma), meningioma, and mesenchymal tumors, causing oncogenic osteomalacia.

Keywords

⁶⁸Ga-DOTATATE - phosphaturic mesenchymal tumor - positron emission tomography - somatostatin receptors - tumor-induced osteomalacia

Introduction

Phosphaturic mesenchymal tumors (PMTs) are very rare tumors, but frequently result in a paraneoplastic syndrome called tumor-induced osteomalacia (TIO).[1] Tumor cells overproduce fibroblast growth factor 23 (FGF23), which is ultimately responsible for metabolic changes leading to osteomalacia. Patients often present with nonspecific bone pain, gradual-onset muscle weakness, and pathologic fractures. PMTs are usually very small and highly variable in location. The most useful imaging modalities to localize PMTs utilize their expression of somatostatin receptors (SSTRs) 1–5, including octreotide scintigraphy and more recently ⁶⁸Ga-DOTATATE positron emission tomography/computed tomography (PET/CT). ⁶⁸Ga-DOTATATE allows vastly improved spatial resolution and precise tumor localization with PET/CT and has relatively high sensitivity and specificity. Imaging is indicated in patients presenting with TIO or patients with suspected PMT recurrence. The purpose of this case report is to emphasize the advantage of ⁶⁸Ga-DOTATATE PET/CT over octreotide scintigraphy in localizing PMTs.

Case Report

An elderly male initially presented with bilateral tibial pain 14 years ago. Leg radiographs were negative, but a bone scan was positive for bilateral tibial stress fractures, and bone densitometry revealed diffuse osteopenia. He was found to have hypophosphatemia (1.9 mg/dl; normal 2.5–4.5) and phosphaturia (urine phosphate 1490 mg/24 h; normal 300–1300). In order to evaluate TIO, an111 Indium-octreotide scan was performed 2 years later but returned negative [Figure 1]. FGF23 levels were not measured during the patient's initial workup. Subsequently, he suffered nontraumatic rib-and-foot fractures. An unenhanced magnetic resonance imaging (MRI) performed for the left hip pain 7 years ago presumed benign fibro-osseous lesion versus enchondroma in the left ischium [Figure 2]. Following surgery for left Cam-type femoroacetabular impingement, he had a femur neck fracture that was instrumented. CT and contrast-enhanced MRI performed for persistent left ischial pain were concerning for chondroid neoplasm [Figure 3]. Incisional biopsy performed 6 years ago revealed mesenchymal tumor, mixed connective tissue type, probably PMT. Hypophosphatemia gradually resolved following surgery, until recently, when serum phosphorus level dropped to 2.3 mg/dl (normal 2.5–4.5 mg/dL). ⁶⁸Ga-DOTATATE PET/CT scan revealed radiotracer uptake in the left ischium suggesting the recurrence of PMT, the initial cause for TIO in this patient [Figure 4].

Figure 1 Coronal maximum intensity projection images of the initial octreotide scan. No abnormal octreotide uptake was seen

Figure 2 Coronal short tau inversion recovery (a) and axial T2 images (b) of magnetic resonance imaging through left ischium demonstrating slight short tau inversion recovery hyperintense lesion (red arrow)

Figure 3 Preincisional biopsy imaging examinations. Axial computed tomography image (a) showing osteolytic lesion in the left ischium with internal matrix small calcifications and disruption of medial cortex. Sagittal T1 (b) and axial T1 (c) magnetic resonance imaging images showing left ischial-enhancing T1 hypointense lesion (orange arrow) (d). Metal-related artifacts on computed tomography and magnetic resonance are noted from left femur neck instrumentation

Figure 4 Most recent ⁶⁸Ga-DOTATATE positron emission tomography/computed tomography. Anatomic axial computed tomography image (a) showing mixed lytic and sclerotic focus in the left ischium (orange arrow) that shows corresponding focal increased uptake on the fused positron emission tomography images (b-d) and maximum intensity projection image (e)

Discussion

We describe a case of recurrent PMT-related TIO which showed focal uptake on ⁶⁸Ga-DOTATATE PET/CT, but the initial tumor occurred prior to Food and Drug Administration approval of DOTATATE scan and was not localized by octreotide scintigraphy.

While a few hundred cases of TIO have been reported, its true prevalence is unknown. The overexpressed FGF23 by mesenchymal tumors is produced by osteogenic cells, osteoblasts, and osteocytes.[2] FGF23 inhibits renal 1α-hydroxylation of 25-hydroxyvitamin D, reducing renal phosphate reabsorption and resulting in renal phosphate wasting, osteoblast downregulation, and mobilization of calcium and phosphate from bones.[2] The mixed connective tissue variant of PMT is the most common subtype and typically benign; however, malignant variants have been described. Patients present with progressive nonspecific symptoms and multiple fractures, often for many years before being diagnosed.[3]

The tumor can be located anywhere in the body, involving any soft tissue or bone, and its size is usually very small. This makes tumor localization in the body extremely difficult. Any imaging examination performed to localize a PMT needs to cover the entire body, from head to toe. Conventional imaging, including radiographs, CT, and MRI, reveal osteomalacia but rarely localize mesenchymal tumor, as does the bone scintigraphy.[4]

111 Indium-octreotide has a high affinity for the somatostatin subtype 2 and 5 receptors, and therefore111 Indium-octreotide scintigraphy, combined with single-photon emission CT, can be a valuable modality.[5] The sensitivity and specificity for this examination, however, are only 36.3% and 80%, respectively.[6] Fluorodeoxyglucose (FDG)-PET/CT is very sensitive but nonspecific, as increased metabolic uptake related to active fracture healing may also demonstrate increased tracer uptake.[6]

DOTATATE has a relatively higher affinity for SSTR2 than SSTR5. Immunohistochemical studies have shown that PMT in TIO demonstrates strong diffuse positive staining for SSTR2A.[7] Like the octreotide, ⁶⁸Ga-DOTATATE (which uses octreotate instead of octreotide) is an SSTR antagonist which is internalized upon receptor binding.[8] As a result, there is accumulation of radioactivity within the tumor cells. ⁶⁸Ga being a positron emitter, a type of beta decay, provides greater resolution compared to111 Indium, which is a gamma-ray emitter. This high SSTR2 affinity and positron-emitting property of ⁶⁸Ga-DOTATATE provide relatively better sensitivity and specificity in localizing PMTs. In addition, ⁶⁸Ga-DOTATATE PET/CT imaging has a shorter acquisition time as well as a shorter half-life (68 min compared to 2.8 days for111 In) and therefore lower radiation exposure.[9] Sensitivity and specificity of ⁶⁸Ga-DOTATATE have been shown to be 83.3%–100% and 100%, respectively, as compared to 50% for FDG-PET/CT.[10]

Differential diagnosis for TIO includes renal Fanconi syndrome and heavy metal poisoning. Normal levels of FGF23 can confirm the diagnosis. Treatment relies on complete tumor excision, which is almost always curative and results in rapid resolution of symptoms. However, cases of recurrence and metastases have been reported. Diagnosis is assisted by measuring serum and urine phosphate and FGF23 levels and may suggest TIO, but PMT localization often presents its own challenges.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Conflict of Interest

There are no conflicts of interest.

Financial support and sponsorship

Nil.

• References

• 1 Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: An analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004;28:1-30.
• 2 Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63.
• 3 Jan de Beur SM. Tumor-induced osteomalacia. JAMA 2005;294:1260-7.
• 4 Garcia CA, Spencer RP. Bone and in-111 octreotide imaging in oncogenic osteomalacia: A case report. Clin Nucl Med 2002;27:582-3.
• 5 Wild D, Mäcke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: A first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005;32:724.
• 6 El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-Delisle C, Merkel R, et al. 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab 2016;101:3575-81.
• 7 Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone 2014;64:222-7.
• 8 Dalm SU, Nonnekens J, Doeswijk GN, de Blois E, van Gent DC, Konijnenberg MW, et al. Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models. J Nucl Med 2016;57:260-5.
• 9 Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 2015;35:500-16.
• 10 Jadhav S, Kasaliwal R, Lele V, Rangarajan V, Chandra P, Shah H, et al. Functional imaging in primary tumour-induced osteomalacia: Relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: A series of nine patients. Clin Endocrinol (Oxf) 2014;81:31-7.

Publication History

Received: 23 October 2011

Accepted: 09 November 2018

Article published online:
19 April 2022